Epstein-barr virus-induced posttransplant lymphoproliferative disorders

Carlos V. Paya, John J. Fung, Michael A. Nalesnik, Elliott Kieff, Michael Green, Gregory Gores, Thomas M. Habermann, Russell H. Wiesner, Lode J. Swinnen, E. Steve Woodle, Jonathan S. Bromberg

Research output: Contribution to journalArticle

Abstract

Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

Original languageEnglish (US)
Pages (from-to)1517-1525
Number of pages9
JournalTransplantation
Volume68
Issue number10
DOIs
StatePublished - Nov 27 1999

    Fingerprint

ASJC Scopus subject areas

  • Transplantation

Cite this

Paya, C. V., Fung, J. J., Nalesnik, M. A., Kieff, E., Green, M., Gores, G., Habermann, T. M., Wiesner, R. H., Swinnen, L. J., Woodle, E. S., & Bromberg, J. S. (1999). Epstein-barr virus-induced posttransplant lymphoproliferative disorders. Transplantation, 68(10), 1517-1525. https://doi.org/10.1097/00007890-199911270-00015